奥沙利铂联合卡培他滨治疗老年胃肠恶性肿瘤的临床疗效分析  

Clinical Efficacy of Oxaliplatin Combined with Capecitabine for Elderly Patients with Gastrointestinal Malignant Tumor

作　　者：卓恩挺[1] 陈雪莲[1] 王连臣[1] 刘松平[1] 符国宏[1] 

机构地区：[1]海南省三亚市农垦三亚医院(海南省第三人民医院)普通外科,572000

出　　处：《实用癌症杂志》2013年第6期686-688,共3页The Practical Journal of Cancer

摘　　要：目的探讨奥沙利铂联合卡培他滨治疗老年胃肠恶性肿瘤的临床疗效。方法将76例老年胃肠恶性肿瘤患者随机分为2组,即观察组38例,对照组38例。对照组患者采用奥沙利铂联合5-氟尿嘧啶化疗,观察组患者采用奥沙利铂联合卡培他滨化疗。治疗后,分别对2组患者的临床治疗效果及不良反应进行评价。同时,对患者进行随访,观察并统计2组患者治疗后的无进展生存时间(PFS)和总生存期(OS)。结果观察组患者临床治疗的总有效率为81.6%,对照组为60.5%,2组比较,差异具有统计学意义(P<0.05)。观察组患者治疗后,恶心呕吐、肝功能异常、感觉神经异常、白细胞减少、血小板减少及口腔黏膜炎不良反应发生率依次为18.4%、21.0%、50.0%、21.0%、31.6%、18.4%,对照组依次为57.9%、60.5%、73.7%、44.7%、52.6%、39.5%,2组比较,差异具有统计学意义(P<0.05)。观察组患者的平均PFS和OS依次为(5.5±1.2)、(10.5±2.2)个月,对照组依次为(3.5±1.2)、(8.3±2.3)个月,2组比较,差异有统计学意义(P<0.05)。结论奥沙利铂联合卡培他滨治疗老年胃肠恶性肿瘤的临床疗效显著,且不良反应发生率较低,能有效延长患者的无进展生存时间和总生存期,值得临床推广与应用。Objective To investigate the efficacy of oxaliplatin combined with capecitabine for the treatment elderly patients with gastrointestinal malignant tumor. Methods 76 cases of elderly patients with gastrointestinal malignant tumor were randomly divided into the observation group and the control group, each with 38 cases. The control group were treated by 5- fluorouracil and oxaliplatin, and the observation group received oxaliplatin combined with capecitabine. After treatment, curative effects and adverse reactions of the 2 groups were evaluated. Progressian-free survival （ PFS ） and overall survival （ OS ） of patients of the 2 groups were observed during follow-up. Results The total effective rate of the observation group and the control group were 81.58 % and 60.53 % , there had statistical difference between the 2 groups （P 〈 0. 05 ）. The incidence rates of nausea and vomiting,abnormal liver function, abnormal sensory nerve, leukopenia, thrombocytopenia and oral mucositis of the observation group were 18.42%, 21.05%, 50.00%, 21.05%, 31.58%, 18.42%, and those of the control group were 57.89%, 60.53%, 73.68 % ,60.53 %, 52.63 %, 39.47 %, there had statistical difference between the 2 groups （ P 〈 0. 05 ）. The median PFS and OS of the observation group and the control group were（5.5 ± 1.2） months, （ 10.5 ± 2.2） months, and（ 3.5 ± 1.2） months, （ 8.3 ± 2.3 ） months, there had statistical difference between the 2 groups （P 〈 0.05 ）. Conclusion Oxaliplatin combined therapy with capecitabine for elderly patients with gastrointestinal malignant tumor is effective with fewer adverse reactions, and it can effectively prolong the patient＇s progression-free survival and overall survival. It is worthy of clinical application.

关 键 词：胃肠恶性肿瘤 老年 奥沙利铂 卡培他滨 

分 类 号：R735.2[医药卫生—肿瘤]